Online inquiry

IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ214MR)

This product GTTS-WQ214MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ214MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11918MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ7403MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ8029MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ1152MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ1435MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ877MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ9509MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ15110MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SYD985
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW